Thus, if high levels of soluble MICB are present in the serum of cervical cancer patients, and this contributes to tumor immune escape, targeting of this molecule could be a promising alternative to improve tumor immunosurveillance in these patients. This evidence concerns the gene MICB and neoplasm.